20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
Ref.: C.L.21.2022
The World Health Organization (WHO) presents its compliments to Member States and
has the honour to invite them to support data collection at country level in order to update
COVID-19 Technology Access Pool (C-TAP) database.
The C-TAP database is critical to ensure further engagement with technology holders, as
well as being a valuable one-stop-shop source of information for Member States and different
stakeholders to contribute to the pandemic response.
The information required will be related to specific COVID-19 technologies national
regulatory status, national Emergency Use Listing (EUL) or equivalent, patent status
information, and market exclusivities (test data protection) if applicable in the country.
To facilitate data collection from countries, the C-TAP Secretariat has developed the
… attached table to obtain and compile information for priority products for C-TAP purposes.
Member States are requested to complete the table and to nominate a focal point to coordinate
further updates.
The completed table and focal point nomination should be sent by email to:
[email protected] by 30 April 2022. Enquiries regarding this process can also be sent to
this email address.
The World Health Organization takes this opportunity to renew to Member States the
assurance of its highest consideration.
GENEVA, 20 April 2022
ENCL.: (1)
National Any market National patent or
National Emergency Use exclusivities (e.g. patent applications
Product
Product name (INN or standard nomenclature) regulatory status Listing (EUL) or Test Data status (Expiry date,
Type
(Y or N) equivalent (Y or Protection), Y or granted, opposed,
N) N (Expiry date) filed, etc.)
Camostat Therapeutic
Molnupiravir Therapeutic
Fluvoxamine Therapeutic
Baricitinib Therapeutic
Empagliflozin Therapeutic
Sotrovimab Therapeutic
Casirivimab Therapeutic
Imdevimab Therapeutic
Casirivimab/ Imdevimab Therapeutic
Tocilizumab Therapeutic
Sarilumab Therapeutic
Nitazoxanide (High dose) Therapeutic
Fluoxetine (IP/OP) Therapeutic
Bicalutamide Therapeutic
Enzalutamide Therapeutic
Enzalutamide Therapeutic
Aviptadil Therapeutic
Ensovibep Therapeutic
MP0423 Therapeutic
Oral NAVs (PF-07321332*) NIRMATRELVIR Therapeutic
AZD7442 (tixagevimab (AZD8895) and cilgavimab
Therapeutic
(AZD1061)
Remdesivir Therapeutic
Soberana 01, Soberana 02 (FINLAY-FR-1) Vaccine
Soberana Plus (FINLAY-FR-1) Vaccine
Soberana Plus (FINLAY-FR-1A) Vaccine
CoV2 preS dTM-AS03 vaccine Vaccine
Page 1 of 6
National Any market National patent or
National Emergency Use exclusivities (e.g. patent applications
Product
Product name (INN or standard nomenclature) regulatory status Listing (EUL) or Test Data status (Expiry date,
Type
(Y or N) equivalent (Y or Protection), Y or granted, opposed,
N) N (Expiry date) filed, etc.)
CIGB-66 (RBD+aluminium hydroxide) Vaccine
GBP510, a recombinant surface protein vaccine with Vaccine
adjuvant AS03 (aluminium hydroxide)
Ad26.COV2.S (Ad26COVS1, JNJ-78436735) Vaccine
Recombinant sars-cov-2 fusion protein vaccine Vaccine
(v-01)
ARCoV (Walvax COVID-19 vaccine) Vaccine
SARS-CoV-2 mRNA vaccine (ARCoV) Vaccine
ARCT-154 mRNA Vaccine Vaccine
ChAdOx1-S – (AZD1222) (Vaxzevria, ChAdOx1 Vaccine
nCoV-19)
AZD2816; adenoviral vector ChAdOx platform and Vaccine
based on the Beta (B.1.351) variant
Inactivated SARS-CoV-2 vaccine (Vero cell), Vaccine
vaccine name BBIBP-CorV (Covilo)
SCB-2019 + AS03 or CpG 1018 adjuvant plus Alum Vaccine
adjuvant (Trimeric subunit Spike Protein vaccine)
Ad5-nCoV (Convidecia) Vaccine
Coronovac+flu vaccine+pneumicoccla vaccine Vaccine
COVAX-19® Recombinant spike protein + adjuvant Vaccine
(SpikoGen)
Covaxin (BBV152) Vaccine
Covishield (ChAdOx1_nCoV-19) Vaccine
COVI-VAC Vaccine
Zorecimeran (INN) concentrate and solvent for Vaccine
dispersion for injection; Company code:
CVnCoV/CV07050101
CVnCoV Vaccine Vaccine
Delns1-2019-ncov-rbd-opt1 Vaccine
Page 2 of 6
National Any market National patent or
National Emergency Use exclusivities (e.g. patent applications
Product
Product name (INN or standard nomenclature) regulatory status Listing (EUL) or Test Data status (Expiry date,
Type
(Y or N) equivalent (Y or Protection), Y or granted, opposed,
N) N (Expiry date) filed, etc.)
DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu- Vaccine
based-RBD )
EpiVacCorona (EpiVacCorona vaccine based on Vaccine
peptide antigens for the prevention of COVID-19)
Inactivated SARS-CoV-2 vaccine FAKHRAVAC Vaccine
(MIVAC)
FINLAY-FR-2 anti-SARS-CoV-2 Vaccine (RBD Vaccine
chemically conjugated to tetanus toxoid plus
adjuvant)
GRAd-COV2 (Replication defective Simian Vaccine
Adenovirus (GRAd) encoding S)
GX-19N Vaccine
rVSV-SARS-CoV-2-S Vaccine (IIBR-100) (Brilife) Vaccine
Bbibp-corv Is this same as entry A54 Vaccine
Ev71 vaccine+inactivated sars-cov-2 vaccine (vero Vaccine
cell)
Inactivated SARS-CoV-2 vaccine (Vero cell) Vaccine
BECOV2 Vaccine
COVID-19 inactivated vaccine, (CovIran-Barkat) Vaccine
Coronavirus-Like Particle COVID-19 (CoVLP) Vaccine
mRNA-1273 Vaccine
mRNA-1273+9vHPV vaccine Vaccine
mRNA-1273+casirivimab+imdevimab Vaccine
mRNA-1273+Ofatumumab Vaccine
mRNA-1273.211 Vaccine
mRNA-1273.211. A multivalent booster candidate Vaccine
combining mRNA-1273 plus mRNA-1273.351.
mRNA-1273.351. Vaccine
A lipid nanoparticle (LNP)-encapsulated mRNA-
Page 3 of 6
National Any market National patent or
National Emergency Use exclusivities (e.g. patent applications
Product
Product name (INN or standard nomenclature) regulatory status Listing (EUL) or Test Data status (Expiry date,
Type
(Y or N) equivalent (Y or Protection), Y or granted, opposed,
N) N (Expiry date) filed, etc.)
based vaccine that encodes for a full-length,
prefusion stabilized S protein of the SARS-CoV-2
B.1.351 variant.
Nanocovax Vaccine
Recombinant Sars-CoV-2 Spike protein, Aluminum Vaccine
adjuvanted (Nanocovax)
SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length Vaccine
recombinant SARS CoV-2 glycoprotein nanoparticle
vaccine adjuvanted with Matrix M)
NVX-CoV2373 (Nuvaxovid)
PCV-13 Vaccine
QazCovid-in® - COVID-19 inactivated vaccine Vaccine
Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S) Vaccine
Razi Cov Pars, recombinant spike protein Vaccine
Flu vaccine+recombinant sars-cov-2 vaccine (cho Vaccine
cell)
Recov - recombinant two-component covid-19 Vaccine
vaccine (cho cell)
SCTV01C. A Bivalent Recombinant Trimeric S Vaccine
Protein vaccine against SARS-CoV-2 Variants
CoronaVac; inactivated SARS-CoV-2 vaccine (vero Vaccine
cell)
COVID-19 mRNA vaccine (nucleoside-modified) Vaccine
(Spikevax)
Sputnik light Is this same as A100 Vaccine
COVID-Vac Combined Vector Vaccine vs (2) Gam- Vaccine
COVID-Vac (Sputnik Light)
AG0301-COVID19 Vaccine
COVID-19 mRNA vaccine (nucleoside-modified) Vaccine
AG0302-COVID19 Vaccine
Page 4 of 6
National Any market National patent or
National Emergency Use exclusivities (e.g. patent applications
Product
Product name (INN or standard nomenclature) regulatory status Listing (EUL) or Test Data status (Expiry date,
Type
(Y or N) equivalent (Y or Protection), Y or granted, opposed,
N) N (Expiry date) filed, etc.)
BNT162b2 (3 LNP-mRNAs ), also known as Vaccine
Tozinameran,”Comirnaty”
BNT162b2+pneumicoccal vaccine Vaccine
BNT162b2 and b3 is it same as BNT 160 Vaccine
(Tozinameran, Comirnaty)
Ad5-nCoV+ZF2001 Vaccine
Recombinant novel coronavirus vaccine (Adenovirus Vaccine
type 5 vector) (Convidecia)
INO-4800+electroporation Vaccine
LYB001 Vaccine
Arct-021 Vaccine
MVC-COV1901 (Spike-2P protein + adjuvant CpG Vaccine
1018)
Sputnik V (Gam-COVID-Vac) Vaccine
VAT00002: SARS-CoV-2 S protein with adjuvant Vaccine
Cpg 1018/alum adjuvant+scb-2019 Vaccine
SCB-2019 Vaccine
Corbevax Vaccine
UB-612 (Multitope peptide based S1-RBD-protein Vaccine
based vaccine)
SARS-CoV-2 vaccine (vero cells) (KCONVAC, Vaccine
KconecaVac)
SARS-CoV-2 VLP Vaccine Vaccine
Inactivated SARS-CoV-2 vaccine (Vero cell) Vaccine
Recombinant SARS-CoV-2 vaccine (CHO Cell) Vaccine
(Recombinant COVID-19 Vaccine (CHO cell, NVSI-
06-08 (ZF2001)
RBD (baculovirus production expressed in Sf9 cells) Vaccine
Recombinant SARS-CoV-2 vaccine (Sf9 Cell)
Page 5 of 6
National Any market National patent or
National Emergency Use exclusivities (e.g. patent applications
Product
Product name (INN or standard nomenclature) regulatory status Listing (EUL) or Test Data status (Expiry date,
Type
(Y or N) equivalent (Y or Protection), Y or granted, opposed,
N) N (Expiry date) filed, etc.)
Recombinant SARS-CoV-2 vaccine (Sf9 Cell) Is this Vaccine
same as A 62
TURKOVAC SARS-COV-2 vaccine Vaccine
ERUCOV-VAC, inactivated virus (Turkovac) Vaccine
VLA2001 Vaccine
nCov vaccine (ZyCoV-D) Vaccine
Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2) Vaccine
Is this A89
Antigen protein Vaccine
COVID-19 vaccine Is this A 93 Vaccine
Sinopharm Vaccine
Viral vector covid-19 vaccine Vaccine
Page 6 of 6
Saatja: <
[email protected]>
Saadetud: 22.04.2022 13:07
Koopia: <
[email protected]>
Teema: WHO: C.L.21.2022 (C-TAP)
Dear Member States of the World Health Organization,Please find attached,
in the six official languages, C.L.21.2022 regarding data collection for
updating COVID-19 Technology Access Pool (C-TAP) database.Should you have
questions regarding C.L.21.2022 please send an email to .Best
regards,Department of Governing BodiesWorld Health Organization***DO NOT
REPLY TO THIS E-MAIL. YOU WILL NOT RECEIVE A REPLY***